InMed Pharmaceuticals Inc. 8-K Filing Report: Key Financial Insights (Dec 2024)

Here are the key insights extracted from the provided financial report section:

1. Entity Information:

• Company Name: InMed Pharmaceuticals Inc.
• CIK: 0001728328
• SEC File Number: 001-39685
• EIN: 98-1428279
• Address: Suite 1445 - 885 West Georgia Street, Vancouver, CA V6C 3E8
• Contact Number: 604-669-7207

2. Filing Type:

• Filing Date: December 18, 2024
• Filing Type: Form 8-K (This form is used to report major events that shareholders should know about).

3. Financial Metrics:

• Period: The report is as of December 18, 2024.
• Currency: Amounts are reported in United States Dollars (USD).
• Shares: The common shares are noted as having no par value.

4. Stock Information:

• Ticker Symbol: INM
• Exchange: NASDAQ

5. Miscellaneous:

• There are no indications of false statements in the provided data (all 'false' entries for various flags).
• The report is structured in XML format, using XBRL for financial reporting compliance.

Insights:

• The filing is timely, as it is an 8-K which suggests that it pertains to a significant event or update regarding InMed Pharmaceuticals that could affect investors.
• The absence of par value for common shares may indicate flexibility in capital structuring.
• Being listed on NASDAQ under the ticker INM allows for scrutiny and provides access to a wider range of investors.

This summary presents a concise overview of the essential data related to InMed Pharmaceuticals as of the specified date.